

Serial No. 09/\_\_\_\_\_

**REMARKS/ARGUMENTS**

Claims 1-3 have been canceled. New claims 4-14 have been added to this application.

Applicants herewith request allowance of the above-captioned application. It is believed that the claims proffered with this Preliminary Amendment place the application in condition for allowance.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made".

Respectfully submitted,

By: \_\_\_\_\_

Paul A. Coletti  
Reg. No. 32,019

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2815  
Dated: June 4 2001

Serial No. 09/ \_\_\_\_\_

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Title:**

Please change the title of the present application to:

-- STENT WITH THERAPEUTICALLY ACTIVE DOSAGE OF RAPAMYCIN COATED THEREON--.

**In the Specification:**

Page 1, between the title and line 9, insert the following:

-- Cross Reference to Related Applications

This application is a continuation application of U.S. Serial No. 09/061,568, filed April 16, 1998. --

On page 8, line 14, please change "1A" to -- 1a -- as follows:

The invention will be better understood in connection with the following figures in which Figures 1 and 1[A] a are top view and section views of a stent containing reservoirs as described in the present invention;

On page 8, line 33, please change "10" to -- 40 -- as follows:

Conversely, stents have proven useful in preventing reducing the proliferation of restenosis. Stents, such as the stent [10] 40 seen in layout in Figure 4, balloon- ....

Please find an Information Disclosure Statement filed with respect to the current application.

**Formal Drawings:**

Please find a new set of Formal Drawings enclosed herewith.

**In the Claims:**

Please cancel Claims 1-3 and add the following new set of claims:

-- 4. (New) A stent having a coating containing rapamycin, said coating formed from a polymer mixed carrier containing the rapamycin; and said coating applied to said stent.

5. (New) The stent of claim 4 wherein said rapamycin is contained in the coating at a weight percentage of 0.0001% to 30%.

Serial No. 09/\_\_\_\_\_

6. (New) The stent of claim 4 wherein the polymer is biocompatible and degradable.
7. (New) The stent of claim 6 wherein the polymer is chosen from: lactone-based polyesters, lactone-based copolyesters, polyanhydrides; polyaminoacids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers; and blends of such polymers.
8. (New) The stent of claim 4 wherein the polymer is nonabsorbable.
9. (New) The stent of claim 8 wherein the polymer is chosen from: polydimethylsiloxane; poly(ethylene)vinylacetate; poly(hydroxy)ethylmethacrylate, polyvinyl pyrrolidone; polytetrafluoroethylene; and cellulose esters.
10. (New) The stent of claim 4 wherein the stent is dip-coated.
11. (New) The stent of claim 4 wherein the stent is sprayed with said coating.
12. (New) The stent of claim 4 further comprising:  
a generally thin walled cylinder, said cylinder containing a plurality of generally solid struts, said applied to said strut, and a channel formed in at least one of said struts, said channel having a closed perimeter on all sides and an open top, and said channel smaller in all dimensions than said strut, said channel containing a reservoir of said rapamycin coating applied therein.
13. (New) The stent of claim 4 wherein the coating is applied to the inside and the outside of the stent.
14. (New) A method for applying a stent in the body comprising:  
mixing rapamycin to a polymer based coating;  
said polymer based coating containing rapamycin in the amount of a weight ration of 0.0001% to about 30%;  
applying said coating to said stent; and  
expanding said stent within the body. --